Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

  title={Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease},
  author={William Bara‐Jimenez and Tzvetelina D Dimitrova and A Sherzai and Antonella Favit and Maral M. Mouradian and Thomas Newell Chase},
  journal={Movement Disorders},
Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double‐blind, placebo‐controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration… 
Monoamine Reuptake Inhibitors in Parkinson's Disease
This review article summarises all of the available literature on use of 50 MAUIs in PD and concludes that selective serotonin transporter (SERT), selective noradrenaline transporter (NET), and dual SERT/NET inhibitors are effective against PD depression.
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
It is possible that inhibition of dopamine reuptake alone does not provide clinical benefit in early Parkinson's disease, adequate inhibition of serotonin and norepinephrine was not achieved in this study, or countervailing physiologic mechanisms offset the potential benefit.
Glutamate release inhibition ineffective in Levodopa‐induced motor complications
In a 3‐week, double‐blind, proof‐of‐concept study, riluzole failed to alter parkinsonian or levodopa‐induced motor complication severity and opposing effects of a generalized inhibition of glutamate‐mediated synaptic transmission may limit the usefulness of this approach to treat PD.
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Patients with PD in advanced stages showed modest improvements in UPDRS subscale II plus subscale III total score and in off time when treated with tesofensine, but a dose-response relationship could not be established for efficacy, while adverse drug reactions tended to be more frequent at higher dosages.
Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of Nonhuman Primate Studies and Clinical Trials
Alternative approaches to dopamine replacement in parkinsonism generally and to wearing-off and dyskinesia are urgently needed, and a hypothesis as to how tailoring the selectivity of DAT inhibitors might maximize the benefits of Dat inhibition in PD is proposed.
Pharmacological treatment of Parkinson’s disease: life beyond dopamine D2/D3 receptors?
Questions and concerns are raised about the true reliability of animal studies, the adequacy of the working hypotheses and design of clinical trials, the validity of tools in current use to evaluate a particular effect, and the selectivity of the drugs used.
Established therapies and novel targets in the treatment of Parkinson’s disease
No effective neuroprotective therapy for Parkinson’s disease is yet available, and there is currently substantial interest in the development of new nondopaminergic agents.
Drug Insight: new drugs in development for Parkinson's disease
The numerous drugs in development that target the primary motor disorder in Parkinson's disease are discussed, including 'neuroprotective' drugs that are capable of blocking or at least slowing down the degenerative process that is responsible for cellular death.
Noradrenaline and Parkinson's Disease
It is argued that the loss of NA neurons in PD has an impact on all PD symptoms and that the addition of NAergic agents to dopaminergic medication could be beneficial in the treatment of the disease.
From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease.
  • P. Jenner
  • Psychology, Biology
    Parkinsonism & related disorders
  • 2009


Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
The hypothesis that A(2A) receptor mechanisms contribute to symptom production in PD and that drugs able to selectively block these receptors may help palliate symptoms in levodopa-treated patients with this disorder is supported.
Adenosine A2A receptor antagonist treatment of Parkinson’s disease
The hypothesis that A2A receptor mechanisms contribute to symptom production in PD and that drugs able to selectively block these receptors may help palliate symptoms in levodopa-treated patients with this disorder is supported.
Sertraline for the treatment of depression in parkinson's disease
  • R. Hauser, T. Zesiewicz
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 1997
It is suggested that sertraline may be a useful treatment for depression in PD and as substantial placebo effects can occur in studies of PD and depression, double‐blind studies are warranted.
Bupropion in Parkinson's disease
Bupropion is mildly efficacious in Parkinson's disease, although side effects were frequent and were dose-limiting in five patients, and depression was alleviated in only 5 patients.
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Observations that NMDA receptor antagonists injected into the striatum or given systemically have the ability to act palliatively or prophylactically to alleviate levodopa-induced response alterations support the view that sensitization of striatal NMDA receptors contributes to the pathogenesis of motor dysfunction in Parkinson's disease.
NS-2330 (Neurosearch).
  • U. Thatte
  • Psychology
    Current opinion in investigational drugs
  • 2001
NeuroSearch is developing NS-2330, a compound that increases the activity of dopamine, norepinephrine and acetylcholine, as a potential therapy for Alzheimer's disease (AD) and Parkinson's disease
Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease
An overview of the current understanding of the life cycle of the dopamine molecule is given, covering dopamine synthesis, storage, release, receptor and autoreceptor interactions, and reuptake.